Driven by a deep understanding of precision medicines, Nextech had unique insights into our RNA editing platform and how our lead program for AATD is differentiated from the competition. For AIRNA’s Series B, we valued Nextech’s focus on building resilient companies and investing in transformative therapies. As we transition to a clinical company, I am thankful for Nextech’s financial and strategic support.